Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China flag China · Delayed Price · Currency is CNY
15.47
+0.23 (1.51%)
Aug 20, 2026, 3:00 PM CST

SHA:600535 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
-1,4362,9944,4513,1192,304
Short-Term Investments
-1,404----
Trading Asset Securities
-1,394524.72300.711,1251,487
Cash & Short-Term Investments
4,3544,2343,5184,7514,2443,791
Cash Growth
2.99%20.34%-25.95%11.95%11.95%78.94%
Accounts Receivable
-2,4181,9662,1313,3483,796
Other Receivables
-39.9623.0611.498.989.47
Receivables
-2,4581,9892,1423,3573,805
Inventory
-1,4271,7121,7481,5321,548
Other Current Assets
-111.591.7291.43127.08105
Total Current Assets
-8,2307,3118,7339,2609,249
Property, Plant & Equipment
-3,5463,6483,7693,8834,088
Long-Term Investments
-1,3461,8212,0541,5111,229
Goodwill
---15.8815.88167.08
Other Intangible Assets
-794.39604.17573.64459.43474.54
Long-Term Deferred Tax Assets
-67.0553.175088.2960.79
Long-Term Deferred Charges
-1,3331,4661,4761,1571,193
Other Long-Term Assets
-22.6672.5443.14102.0879.68
Total Assets
-15,34014,97616,71416,47716,542

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
-376.9606.81572.73887.77728.58
Accrued Expenses
-537.57171.05178.38242.79213.15
Short-Term Debt
-1,116699.54814.63201.77188.79
Current Portion of Long-Term Debt
-4.96586.83462.74475.21343.33
Current Portion of Leases
-49.747.8458.5453.9855.67
Current Income Taxes Payable
-110.9157.7818.0484.62108.09
Current Unearned Revenue
-49.8869.8591.6292.3568.33
Other Current Liabilities
-62.39109.98172.88108.72149.12
Total Current Liabilities
-2,3082,3502,3702,1471,855
Long-Term Debt
-216.87253.761,4141,3761,034
Long-Term Leases
-51.1967.9781.5275.3181.63
Long-Term Unearned Revenue
-189.95193.29159.02177.79214.57
Long-Term Deferred Tax Liabilities
-26.020.40.1122.8742.18
Total Liabilities
-2,7922,8654,0243,7993,228

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
-1,4941,4941,5001,5001,513
Additional Paid-In Capital
-482.39458.96958.081,4571,530
Retained Earnings
-10,3919,8989,9299,35110,222
Treasury Stock
----105.98-105.98-251.29
Comprehensive Income & Other
-37.2452.2288211.58-32.19
Total Common Equity
12,76812,40411,90312,36812,41212,981
Minority Interest
-143.49207.86321.59265.12332.56
Shareholders' Equity
12,90612,54812,11112,69012,67813,314
Total Liabilities & Equity
-15,34014,97616,71416,47716,542

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
1,1491,4381,6562,8312,1821,704
Net Cash (Debt)
3,2052,7951,8621,9202,0622,088
Net Cash Growth
26.50%50.10%-2.99%-6.89%-1.23%-
Net Cash Per Share
2.151.871.251.291.401.39
Filing Date Shares Outstanding
1,4941,4941,4941,4941,4941,499
Total Common Shares Outstanding
1,4941,4941,4941,4941,4941,499
Working Capital
-5,9224,9616,3637,1137,394
Book Value Per Share
8.558.307.978.288.318.66
Tangible Book Value
11,99111,61011,29911,77911,93712,340
Tangible Book Value Per Share
8.037.777.567.887.998.23
Buildings
-3,5293,5173,5053,4903,398
Machinery
-3,8033,7633,6253,4723,340
Construction In Progress
-322.42221.76153.87102.96167.85